The brain protective effect of dexmedetomidine during surgery for paediatric patients with congenital heart disease

Jin Gong, Rufang Zhang, Li Shen, Yewei Xie and Xiaobing Li

Abstract
Objective: To study the brain protective effect of dexmedetomidine (DEX) during surgery in paediatric patients with congenital heart disease (CHD).
Methods: This randomized single-blind controlled study enrolled paediatric patients aged 0–3 years with CHD who underwent surgery and randomized them into two groups: one group received DEX and the control group received 0.9% NaCl during anaesthesia. Demographic data, heart rate (HR), mean arterial pressure (MAP) and central venous pressure (CVP) were recorded. Levels of neuron specific enolase (NES) and S-100β protein were determined using enzyme-linked immunosorbent assays.
Results: The study enrolled 80 paediatric patients with CHD. Compared with the control group, HR, MAP and CVP were significantly lower in the DEX group at all time-points except for T0. At all time-points except for T0, the levels of jugular venous oxygen saturation in the DEX group were significantly higher compared with the control group. At all time-points except for T0, the levels of arterial venous difference and cerebral extraction of oxygen were significantly lower in the DEX group compared with the control group. Levels of NES and S-100β protein in the DEX group were significantly lower compared with the control group at all time-points except for T0.
Conclusion: DEX treatment during surgery for CHD improved oxygen metabolism in brain tissues and reduced the levels of NES and S-100β protein.

Keywords
Dexmedetomidine, brain protective, surgery, congenital heart disease

Date received: 16 July 2018; accepted: 4 December 2018

Department of Cardiothoracic Surgery, Shanghai Children’s Hospital, Shanghai Jiaotong University, Shanghai, China

Corresponding author:
Rufang Zhang, Department of Cardiothoracic Surgery, Shanghai Children’s Hospital, Shanghai Jiaotong University, 355 Luding Road, Putuo District, Shanghai 200063, China. Email: zhangrufang_1@yeah.net
Introduction

Congenital heart disease (CHD), which is the most common human congenital malformation, is also the most common cause of infant death due to birth defects with an incidence of approximately 1 in 100 live births.\(^1\)\(^,\)\(^2\) The main treatment for CHD is surgery. However, some inevitable problems associated with surgery often adversely affect the patient, which include stress-induced catabolism resulting from surgical injury, postoperative mortality in patients with delirium, and high hospital costs due to a long stay in the intensive care unit (ICU).\(^3\)\(^-\)\(^5\) Therefore, the pre- and postoperative treatment of children with CHD is very important.

Dexmedetomidine (DEX), an \(\alpha_2\)-adrenergic receptor agonist with sedative, analgesic and anxiolytic properties has been used to provide effective anaesthesia in paediatric ICUs for postoperative nursing, especially during mechanical ventilation and/or sedation-dependent processes as the only sedative or as an adjunct medicine.\(^6\)\(^-\)\(^8\) Previous studies showed that when DEX was used during surgery for CHD patients it resulted in decreased ventilatory time, ICU length of stay and hospital length of stay compared with patients without DEX; and thus could improve the clinical outcomes of children undergoing CHD surgery.\(^9\)\(^-\)\(^11\) Studies have also demonstrated that DEX may have a protective effect on ischaemic brain injury,\(^12\) for which CHD patients undergoing surgery are at a high risk mainly as a result of cardiopulmonary bypass (CPB).\(^13\) However, to the best of our knowledge, no study has focused on the protective effect of DEX on brain injury during surgery for paediatric patients who have CHD.

The current study investigated the effect of DEX on brain protection during surgery for paediatric CHD patients. This current study measured the arterial oxygen content (\(\text{CaO}_2\)), jugular bulb venous oxygen content (\(\text{CjvO}_2\)), the content of arterial venous difference (\(\text{DajvO}_2\)), cerebral extraction of oxygen (\(\text{CERO}_2\)), and the levels of neuron specific enolase (NES) and S-100\(\beta\) protein to determine the effect of DEX on each patient’s level of brain injury.

Patients and methods

Paediatric patient population

This randomized single-blind controlled study enrolled consecutive CHD patients aged 0–3 years who underwent surgery in the Department of Cardiothoracic Surgery, Shanghai Children’s Hospital, Shanghai Jiaotong University, Shanghai, China between July 2014 and December 2016. All patients were randomly divided equally into two groups using a random number table method. The exclusion criteria were as follows: (i) preoperative brain injury or neuroblastoma; (ii) cyanosis; (iii) severe pulmonary arterial hypertension or infection; (iv) respiratory insufficiency or respiratory failure; (v) severe organ dysfunction; (vi) prior use of vasoactive drugs before surgery.

The research was approved by the ethics review committee of Shanghai Children’s Hospital, Shanghai Jiaotong University, Shanghai, China (no. 2014R041-F01). Written informed consent was provided by the parents/legal guardians of the children.

Anaesthesia

Etomidate emulsion (0.3 mg/kg) was administered to all patients by intravenous (i.v.) injection before surgery. After entering the operating room, anaesthesia induction was performed by i.v. injection of 0.05 mg/kg midazolam, 1 \(\mu\)g/kg sufentanil, 0.3 mg/kg etomidate and 0.6 mg/kg rocuronium bromide using a TCI III-B syringe pump (Guangxi VERYARK Technology,
Nanning, China) followed by endotracheal intubation and mechanical ventilation. For the DEX group, 0.5 µg/kg DEX administered by i.v. injection, was used as the loading dose; and a maintenance dose of DEX of 0.5 µg/kg per h was administered by i.v. injection until the surgery was complete. For the control group, 0.9% NaCl was given at a rate of 0.5 µg/kg per h. For both of the two groups, 1%–2% sevoflurane, 0.1–1.0 µg/kg per h sufentanil and 0.1–1.0 µg/kg per h atracurium besylate were used to maintain reasonable levels of anaesthesia. The bispectral index (BIS) for both groups was maintained within 40–50. All procedures were performed under conditions of extracorporeal circulation using a Jostra HL 20 heart-lung machine (Maquet Cardiopulmonary AG, Hirrlingen, Germany) to maintain perfusion during CPB.

Data collection and measurement

Demographic data including age, sex, weight and basic clinical characteristics including pathological type, CPB time and cross-clamp time were recorded for each patient. Heart rate (HR), mean arterial pressure (MAP) and central venous pressure (CVP) were recorded. Levels of arterial oxygen saturation (SO2) and jugular venous oxygen saturation (SjvO2) were measured by blood gas analysis using a blood gas analyser (GEM Premier3000, Instrumentation Laboratory, MA, USA) and values of CaO2, CjvO2, DajvO2 and cerebral CERO2 were calculated and analysed.14 All indices were measured at the following time-points: T0, before anaesthesia induction; T1, at the opening of the ascending aorta; T2, at the end of CPB; T3, at the end of surgery; and T4, at 2 h after surgery. Jugular bulb blood (2 ml at each time-point) was also collected at the above time-points by retrograde catheterization of the right internal jugular vein. The samples were collected in ethylenediaminetetra-acetic acid anticoagulant tubes (Shanghai Orson Medical Technology, Shanghai, China), centrifuged at 1800 g for 10 min at room temperature using an Allegra X-12R centrifuge (Beckman Coulter, Brea, CA, USA) and stored at −70°C until analysis. Plasma levels of NES and S-100β protein were measured by enzyme-linked immunosorbent assays (ELISA) using commercial ELISA kits (both purchased from R&D Systems, Minneapolis, MN, USA) according to the manufacturer’s instructions. The minimum detectable concentrations were 0.038 ng/ml for the NES kit (DENL20) and 0.047 ng/ml for the S-100β kit (DY1820-05). Intra- and interassay coefficients of variation for all ELISAs were <8% and <6% for NES and were <7% and <6% for S-100β, respectively.

Statistical analyses

All statistical analyses were performed using IBM SPSS Statistics for Windows®, version 19.0 (IBM, Armonk, NY, USA). All data are presented as mean ± SD. Comparisons between two groups were conducted using the Student’s t-test. Comparisons between three or more groups were conducted using one-way analysis of variance followed by Tukey’s post-hoc test. χ2-test was used to compare the categorical data. A P-value < 0.05 was considered statistically significant.

Results

This randomized single-blind controlled study enrolled 80 paediatric patients with CHD. As shown in Table 1, all patients were randomly divided into two groups: the DEX group with a mean ± SD age of 2.1 ± 1.1 years (26 males and 14 females); and the control group with a mean ± SD age of 2.3 ± 1.4 years (25 males and 15 females). Among all patients, 24 (30.0%) were diagnosed with a ventricular septal defect, 23 (28.8%) were diagnosed with ventricular septal defect / patent ductus
arteriosus, 12 (15.0%) were diagnosed with coarctation of the aorta, 11 (13.8%) were diagnosed with a complete atrioventricular canal defect and 10 (12.5%) were diagnosed with a double outlet right ventricle. All basic clinical characteristics including CPB time and cross-clamp time during the surgical procedure showed no significant differences between the two groups.

When HR, MAP and CVP were compared between the two group, the results showed that for all three indices, the levels decreased significantly at T1 compared with T0 in both groups (\(P < 0.05\) for all comparisons) (Table 2). The levels then increased during the remaining time-points. The values of the three indices were all significantly lower in the DEX group compared with the control group at all time-points except for T0 (\(P < 0.05\) for all comparisons).

To study the effect of DEX on cerebral oxygen metabolism, the levels of SjvO\(_2\), DajvO\(_2\), and CERO\(_2\) in the two groups of patients were analysed at different time-points. The results showed that in both groups, the levels of SjvO\(_2\) were significantly increased at T1 compared with T0 (\(P < 0.05\) for both comparisons) (Table 3). The levels of SjvO\(_2\) then decreased over the subsequent time-points in both groups, but were significantly higher in the DEX group compared with the control group at all time-points except for T0 (\(P < 0.05\) for all comparisons). In terms of the levels of DajvO\(_2\) and CERO\(_2\), these were both significantly decreased in the two groups at T1 compared with T0 (\(P < 0.05\) for all comparisons), then increased over the subsequent time-points. The levels of DajvO\(_2\) and CERO\(_2\) were significantly lower in the DEX group compared with the control group at all time-points except for T0 (\(P < 0.05\) for all comparisons).

To further investigate the effect of DEX on brain injury, the levels of NES and S-100\(\beta\) in the two groups of patients were analysed at different time-points. As shown in Table 4, the levels of both NES and S-100\(\beta\) in the DEX group were significantly lower in the DEX group compared with the control group at all time-points except for T0 (\(P < 0.05\) for all comparisons).

**Discussion**

There are about 10 000 children who need anaesthesia for CHD surgery during the first year of their lives every year.\(^{15}\) Since brain injury as a result of CPB is a high risk for young children undergoing surgical procedures for CHD, the main focus after infant cardiac surgery is to avoid a low cardiac output state.\(^{16}\) DEX, which is mainly

---

**Table 1.** Demographic and clinical characteristics of paediatric patients (\(n = 80\)) with congenital heart disease who were enrolled in a randomized single-blind controlled study to investigate the protective effect of dexmedetomidine (DEX) on brain injury during surgery.

| Characteristic          | DEX group | Control group |
|-------------------------|-----------|--------------|
|                         | \(n = 40\) | \(n = 40\)   |
| Age, years              | 2.1 ± 1.1 | 2.3 ± 1.4    |
| Sex, male:female        | 26:14     | 25:15        |
| Weight, kg              | 11.3 ± 5.2| 11.8 ± 3.9   |
| Pathological type       |           |              |
| VSD                     | 11 (27.5) | 13 (32.5)    |
| VSD/PDA                 | 12 (30.0) | 11 (27.5)    |
| CoA                     | 7 (17.5)  | 5 (12.5)     |
| CAVC                    | 5 (12.5)  | 6 (15.0)     |
| DORV                    | 5 (12.5)  | 5 (12.5)     |
| Cardiopulmonary bypass time, min | 98.3 ± 15.3 | 99.5 ± 17.8 |
| Cross-clamp time, min   | 59.0 ± 11.9| 58.2 ± 12.1  |

Data presented as mean ± SD or \(n\) of patients (%). VSD, ventricular septal defect; PDA, patent ductus arteriosus; CoA, coarctation of the aorta; CAVC, complete atrioventricular canal defect; DORV, double outlet right ventricle.

No significant between-group differences (\(P \geq 0.05\)); Student’s t-test for continuous data and \(\chi^2\)-test for categorical data.
used for the sedation of patients who are transitioning to tracheal extubation during surgery or in the postoperative period, is now also used for the treatment of CHD patients.\textsuperscript{11,17} However, to the best of our knowledge, most studies have focused on the use of DEX for postoperative sedation of CHD patients and have not investigated the protective effect of DEX on brain injury in children undergoing CHD surgery.\textsuperscript{9–11} In this current investigation, DEX improved oxygen metabolism in the brain as demonstrated by reduced levels of NES and S-100β protein.

**Table 2.** Heart rate (HR), mean arterial pressure (MAP) and central venous pressure (CVP) at different time-points in paediatric patients (n = 80) with congenital heart disease who were enrolled in a randomized single-blind controlled study to investigate the protective effect of dexmedetomidine (DEX) on brain injury during surgery.

| Parameter | Group | T0 | T1 | T2 | T3 | T4 |
|-----------|-------|----|----|----|----|----|
| HR, beats/min | DEX  | 98.5 ± 11.3 | 81.6 ± 12.0  | 89.5 ± 11.3*# | 90.5 ± 12.9*# | 91.9 ± 11.6*# |
| Control   | 97.3 ± 10.9 | 87.2 ± 11.9* # | 92.7 ± 13.4* # | 95.2 ± 15.3 | 97.8 ± 10.7 |
| MAP, mmHg | DEX  | 73.2 ± 9.8 | 64.1 ± 10.5* # | 67.5 ± 11.1* # | 68.1 ± 10.3* # | 70.4 ± 8.7* # |
| Control   | 74.5 ± 10.6 | 69.6 ± 12.7* # | 71.9 ± 10.4* # | 72.6 ± 12.5 | 74.9 ± 11.4 |
| CVP, mmHg | DEX  | 7.2 ± 0.6 | 6.1 ± 1.0* # | 6.6 ± 1.6* # | 6.9 ± 1.1* # | 6.9 ± 1.4* # |
| Control   | 7.3 ± 1.1 | 6.6 ± 1.3* | 7.1 ± 1.9* | 7.3 ± 1.2 | 7.4 ± 1.3 |

Data presented as mean ± SD.
*P < 0.05, compared with T0; #P < 0.05, compared with the control group; Student’s t-test for comparison between two groups and comparisons between three or more groups were conducted using one-way analysis of variance followed by Tukey’s post-hoc test.

**Table 3.** Levels of jugular venous oxygen saturation (SjvO\textsubscript{2}), the content of arterial venous difference (DajvO\textsubscript{2}) and cerebral extraction of oxygen (CERO\textsubscript{2}) at different time-points in paediatric patients (n = 80) with congenital heart disease who were enrolled in a randomized single-blind controlled study to investigate the protective effect of dexmedetomidine (DEX) on brain injury during surgery.

| Parameter | Group | T0 | T1 | T2 | T3 | T4 |
|-----------|-------|----|----|----|----|----|
| SjvO\textsubscript{2}, % | DEX  | 61.2 ± 8.6 | 72.3 ± 9.7* # | 69.2 ± 8.9* # | 64.6 ± 8.1* # | 62.8 ± 6.8* # |
| Control   | 60.4 ± 10.1 | 67.5 ± 7.5* | 65.8 ± 7.4* | 62.1 ± 5.6* | 60.9 ± 6.5* |
| DajvO\textsubscript{2}, mmol/l | DEX  | 52.8 ± 7.2 | 25.6 ± 5.2* # | 34.1 ± 5.3* # | 42.1 ± 7.0* # | 45.6 ± 5.8* # |
| Control   | 53.9 ± 7.3 | 32.7 ± 6.1* # | 49.5 ± 4.9* # | 51.3 ± 6.3* | 52.6 ± 5.4* |
| CERO\textsubscript{2}, % | DEX  | 36.5 ± 6.5 | 25.1 ± 4.3* # | 28.5 ± 5.6* # | 31.4 ± 6.5* # | 32.1 ± 4.3* # |
| Control   | 37.8 ± 5.8 | 31.6 ± 5.6* | 33.5 ± 7.1* | 34.7 ± 6.2* | 36.2 ± 5.3* |

Data presented as mean ± SD.
*P < 0.05, compared with T0; #P < 0.05, compared with the control group; Student’s t-test for comparison between two groups and comparisons between three or more groups were conducted using one-way analysis of variance followed by Tukey’s post-hoc test.
This current study demonstrated that DEX reduced the haemodynamic indices of HR, MAP and CVP. A previous study demonstrated HR, MAP and CVP all showed a significant decrease after treatment with DEX in newborn babies and infants with CHD. An in vivo study conducted in a swine model found that in propofol-sedated animals, DEX significantly decreased the BIS value, MAP, HR, cardiac output and mixed venous oxygen saturation, in a dose-dependent manner. The haemodynamic findings of the current study were consistent with these two previous studies. 

The current study also investigated the effect of DEX on cerebral oxygen metabolism and found that DEX increased the levels of SjvO₂ and decreased the levels of DajvO₂ and CERO₂. Sufentanil combined with DEX increased the levels of SjvO₂ compared with sufentanil alone in a study investigating early postoperative cognitive dysfunction in elderly patients. Another study also demonstrated that DEX could decrease oxygen delivery and oxygen consumption. These findings indicate that DEX can influence cerebral oxygen metabolism and may improve oxygen metabolism in human brain tissues. 

To further investigate the influence of DEX on brain injury, the current study evaluated the levels of NES and S-100β protein during surgery. The results showed that DEX significantly decreased the levels of over-expressed NES and S-100β induced by CPB and thus should reduce the risk of brain injury. S-100β protein, a calcium-binding protein, is mainly generated and released by astrocytes in the central nervous system and increased of S-100β protein indicates either glial injury or astrocytic reactivity to neural damage. Increased NES, a glycolytic pathway enzyme, indicates neuronal and astrocyte damage. Since few studies have focused on the brain protective effects of DEX, it was not possible to find similar studies reporting the influence of DEX on the levels of NES and S-100β protein.

In conclusion, this randomized single-blind controlled study investigated the use of DEX during surgery in paediatric patients with CHD. The current results demonstrated that DEX decreased the HR, MAP and CVP; and it improved oxygen metabolism in brain tissues and reduced the levels of NES and S-100β protein. The study provides preliminary evidence for the use of DEX for brain injury.
protection in CHD patients undergoing surgery, but larger studies are required to confirm these findings.

Declaration of conflicting interest
The authors declare that there are no conflicts of interest.

Funding
This research was supported by Shanghai Science and Technology Commission Research Project (no. 12411952409).

ORCID iD
Rufang Zhang http://orcid.org/0000-0001-6635-1223

References
1. Warburton D, Ronemus M, Kline J, et al. The contribution of de novo and rare inherited copy number changes to congenital heart disease in an unselected sample of children with conotruncal defects or hypoplastic left heart disease. Hum Genet 2013; 133: 11–27.
2. Pan W, Wang Y, Lin L, et al. Outcomes of dexmedetomidine treatment in pediatric patients undergoing congenital heart disease surgery: a meta-analysis. Paediatr Anaesth 2016; 26: 239–248.
3. Glatz AC, Purrington KS, Klinger A, et al. Cumulative exposure to medical radiation for children requiring surgery for congenital heart disease. J Pediatr 2014; 164: 789–794.
4. Kehlet H and Dahl JB. Anaesthesia, surgery, and challenges in postoperative recovery. Lancet 2003; 362: 1921–1928.
5. Wilmore DW. From Cuthbertson to fast-track surgery: 70 years of progress in reducing stress in surgical patients. Ann Surg 2002; 236: 643–648.
6. Shepard SM, Tejman-Yarden S, Khanna S, et al. Dexmedetomidine-related atrial standstill and loss of capture in a pediatric patient after congenital heart surgery. Crit Care Med 2011; 39: 187–189.
7. Tobias JD, Gupta P, Naguib A, et al. Dexmedetomidine: applications for the pediatric patient with congenital heart disease. Pediatr Cardiol 2011; 32: 1075–1087.
8. Lam F, Bhutta AT, Tobias JD, et al. Hemodynamic effects of dexmedetomidine in critically ill neonates and infants with heart disease. Pediatr Cardiol 2012; 33: 1069–1077.
9. Takahashi Y, Ueno K, Ninomiya Y, et al. Potential risk factors for dexmedetomidine withdrawal seizures in infants after surgery for congenital heart disease. Brain Dev 2016; 38: 648–653.
10. Ueno K, Ninomiya Y, Shiokawa N, et al. Dexmedetomidine is associated with an increased incidence of bradycardia in patients with trisomy 21 after surgery for congenital heart disease. Pediatr Cardiol 2016; 37: 1228–1234.
11. Kunisawa T, Kurosawa A, Hayashi D, et al. Administration of dexmedetomidine alone during diagnostic cardiac catheterization in adults with congenital heart disease: two case reports. J Anesth 2011; 25: 599–602.
12. Jiang L, Hu M, Lu Y, et al. The protective effects of dexmedetomidine on ischemic brain injury: a meta-analysis. J Clin Anesth 2017; 40: 25–32.
13. Mulkey SB, Swearingen CJ, Melguizo MS, et al. Multi-tiered analysis of brain injury in neonates with congenital heart disease. Pediatr Cardiol 2013; 34: 1772–1784.
14. Hu Z, Xu L, Zhu Z, et al. Effects of hypothermic cardiopulmonary bypass on internal jugular bulb venous oxygen saturation, cerebral oxygen saturation, and bispectral index in pediatric patients undergoing cardiac surgery: a prospective study. Medicine (Baltimore) 2016; 95: e2483.
15. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics – 2013 update: a report from the American Heart Association. Circulation 2013; 127: e6–e245.
16. Kaltman JR, Andropoulos DB, Checchia PA, et al. Report of the Pediatric Heart Network and National Heart, Lung, and Blood Institute Working Group on the Perioperative Management of Congenital Heart Disease. Circulation 2010; 121: 2766–2772.
17. Jiang L, Ding S, Yan H, et al. A retrospective comparison of dexmedetomidine versus midazolam for pediatric patients with congenital
heart disease requiring postoperative sedation. *Pediatr Cardiol* 2015; 36: 993–999.

18. Sano H, Doi M, Mimuro S, et al. Evaluation of the hypnotic and hemodynamic effects of dexmedetomidine on propofol-sedated swine. *Exp Anim* 2010; 59: 199–205.

19. Lu J, Chen G, Zhou H, et al. Effect of parecoxib sodium pretreatment combined with dexmedetomidine on early postoperative cognitive dysfunction in elderly patients after shoulder arthroscopy: a randomized double blinded controlled trial. *J Clin Anesth* 2017; 41: 30–34.

20. Bohmer AE, Oses JP, Schmidt AP, et al. Neuron-specific enolase, S100B, and glial fibrillary acidic protein levels as outcome predictors in patients with severe traumatic brain injury. *Neurosurgery* 2011; 68: 1624–1630.

21. Grandi C, Tomasi CD, Fernandes K, et al. Brain-derived neurotrophic factor and neuron-specific enolase, but not S100β, levels are associated to the occurrence of delirium in intensive care unit patients. *J Crit Care* 2011; 26: 133–137.